Related Experiment Video
Updated: Jul 1, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
BAFF-targeting therapy, a promising strategy for treating autoimmune diseases
Jian Sun1, Zhou Lin, Jiannan Feng
1Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 30072, PR China. jsun@public3.bta.net.cn
B cell activating factor (BAFF) is crucial for B cell survival and its deregulation is linked to autoimmune diseases. Blocking BAFF activity shows promise in treating conditions like lupus and rheumatoid arthritis.
Area of Science:
- Immunology
- Pathogenesis of Autoimmune Diseases
Background:
- B cell activating factor (BAFF) is a critical regulator of B cell maturation and survival.
- Deregulation of BAFF is implicated in the pathogenesis of B cell-related autoimmune diseases.
Purpose of the Study:
- To highlight the role of BAFF in autoimmune diseases.
- To discuss the therapeutic potential of BAFF-targeting strategies.
Main Methods:
- Review of existing literature on BAFF function and its role in autoimmunity.
- Analysis of preclinical and clinical data on BAFF blockade therapies.
Main Results:
- BAFF plays a key role in the development and maintenance of B cell populations.
- Targeting BAFF has demonstrated significant efficacy in ameliorating autoimmune disease symptoms in models and human trials.
Conclusions:
- BAFF is a critical factor in B cell homeostasis and autoimmunity.
- BAFF-targeted therapy represents a promising therapeutic avenue for B cell-mediated autoimmune diseases.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cell-mediated Immune Responses
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

